AGP Picks
View all

Today in Medicine
Provided by AGP

Today in Medicine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

Press releases published on September 23, 2026

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Sep. 23, 2026

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Indeterminate GlobeNewswire
Entente Education Canada urges federal government to take steps to improve cash flow and tax fairness for seniors, caregiver support
Sep. 23, 2026

Entente Education Canada urges federal government to take steps to improve cash flow and tax fairness for seniors, caregiver support

Indeterminate GlobeNewswire
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Sep. 23, 2026

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

Indeterminate GlobeNewswire
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Sep. 23, 2026

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

Indeterminate GlobeNewswire
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Sep. 23, 2026

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Indeterminate GlobeNewswire
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
Sep. 23, 2026

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

Indeterminate GlobeNewswire
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Sep. 23, 2026

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

Indeterminate GlobeNewswire
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Sep. 23, 2026

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Indeterminate GlobeNewswire
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Sep. 23, 2026

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Indeterminate GlobeNewswire
Verano to Report Third Quarter 2026 Financial Results on October 29, 2026
Sep. 23, 2026

Verano to Report Third Quarter 2026 Financial Results on October 29, 2026

Indeterminate GlobeNewswire
Psyence BioMed Announces Strategic Ibogaine Investment
Sep. 23, 2026

Psyence BioMed Announces Strategic Ibogaine Investment

Indeterminate GlobeNewswire
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Sep. 23, 2026

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Indeterminate GlobeNewswire
Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million
Sep. 23, 2026

Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million

Indeterminate GlobeNewswire
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
Sep. 23, 2026

Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026

Indeterminate GlobeNewswire
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Sep. 23, 2026

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Indeterminate GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
Sep. 23, 2026

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

Indeterminate GlobeNewswire
Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada
Sep. 23, 2026

Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada

Indeterminate GlobeNewswire
La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada
Sep. 23, 2026

La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada

Indeterminate GlobeNewswire
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
Sep. 23, 2026

Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer

Indeterminate GlobeNewswire
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
Sep. 23, 2026

ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Medicine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.